Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $235.00

Sarepta Therapeutics (NASDAQ:SRPTFree Report) had its target price raised by Needham & Company LLC from $166.00 to $235.00 in a report published on Friday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently weighed in on SRPT. Barclays raised their price target on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an overweight rating in a research report on Thursday, February 29th. Citigroup raised their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a buy rating in a research report on Thursday, February 29th. BMO Capital Markets restated an outperform rating and issued a $170.00 price target on shares of Sarepta Therapeutics in a research report on Friday, June 14th. Wedbush restated an outperform rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, Bank of America raised their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a buy rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of Moderate Buy and a consensus price target of $177.65.

Read Our Latest Stock Analysis on Sarepta Therapeutics

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $160.72 on Friday. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The stock has a fifty day moving average price of $125.56 and a 200 day moving average price of $120.18. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a market cap of $15.19 billion, a PE ratio of 1,461.09 and a beta of 0.96.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same period last year, the company earned ($1.44) earnings per share. Sell-side analysts forecast that Sarepta Therapeutics will post 2.99 EPS for the current year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.70% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Capital International Investors lifted its stake in shares of Sarepta Therapeutics by 160.0% in the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock valued at $457,221,000 after purchasing an additional 2,917,797 shares in the last quarter. Farallon Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Norges Bank acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $80,697,000. Bank of Nova Scotia acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $50,990,000. Finally, Avoro Capital Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after purchasing an additional 319,444 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Featured Articles

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.